Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan.
Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Int J Clin Pract. 2021 Apr;75(4):e13945. doi: 10.1111/ijcp.13945. Epub 2021 Jan 19.
Non-invasive techniques for liver fibrosis diagnosis are very important for clinician especially in high-risk patients for liver biopsy. We further explored the diagnostic accuracy of FibroScan, FIB-4 and aminotransferase-to-platelet ratio index (APRI) in identifying liver fibrosis and assess their predictive role for oesophageal varices in patients with hepatocellular carcinoma (HCC).
In total, 380 patients who underwent surgery for HCC were included based on retrospective study design. Liver fibrosis was pathologically diagnosed using the Ishak scoring system. Liver stiffness parameters were measured using FibroScan. APRI and FIB-4 were calculated. Among those, 121 patients who received oesophagogastroduodenoscopic examination underwent variceal evaluation.
For liver cirrhosis diagnosis with FibroScan, the optimal cut-off values for the patients with HCC overall, left HCC and right HCC were 8.85, 11.75 and 8.70 kPa (the accuracy were 78.7%, 78.4% and 79.2%, respectively). They had high areas under the receiver operating characteristic curve of 0.84, 0.84 and 0.85. The combined FibroScan, APRI and FIB-4 had very high specificity (more than 92%) for cirrhosis diagnosis. The optimal cut-off liver stiffness values for the diagnosis of varices were all 11.2 kPa. For predicting varices, the optimal cut-off values of FIB-4 and APRI were 2.64 and 0.71, their accuracy were 64.3%-78.4%, 69.4% and 72.7%, respectively.
FibroScan, FIB-4 and APRI have moderate accuracy for liver fibrosis diagnosis and oesophageal varices prediction in patients with hepatoma. This is a study of these non-invasive techniques applied in specific hepatoma patients and with inevitable limitations and need future more studies for validation.
非侵入性技术在肝纤维化诊断中非常重要,尤其是对于肝活检高危患者的临床医生而言。我们进一步探讨了 FibroScan、FIB-4 和天冬氨酸氨基转移酶与血小板比值指数(APRI)在识别肝纤维化中的诊断准确性,并评估它们在肝细胞癌(HCC)患者中对食管静脉曲张的预测作用。
本研究基于回顾性研究设计,共纳入 380 例行 HCC 手术的患者。采用 Ishak 评分系统对肝纤维化进行病理诊断。使用 FibroScan 测量肝脏硬度参数。计算 APRI 和 FIB-4。其中,121 例接受上消化道内镜检查的患者进行了静脉曲张评估。
对于 HCC 患者的肝硬化诊断,FibroScan 的最佳截断值为整体 HCC、左 HCC 和右 HCC 患者分别为 8.85、11.75 和 8.70kPa(准确性分别为 78.7%、78.4%和 79.2%)。它们的受试者工作特征曲线下面积均为 0.84。FibroScan、APRI 和 FIB-4 联合检测对肝硬化诊断具有很高的特异性(均超过 92%)。诊断静脉曲张的最佳肝硬度截断值均为 11.2kPa。对于预测静脉曲张,FIB-4 和 APRI 的最佳截断值分别为 2.64 和 0.71,其准确性分别为 64.3%-78.4%、69.4%和 72.7%。
FibroScan、FIB-4 和 APRI 对肝癌患者的肝纤维化诊断和食管静脉曲张预测具有中等准确性。这是一项针对特定肝癌患者的非侵入性技术研究,具有不可避免的局限性,需要进一步研究验证。